Robert W. Baird reiterated their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. They currently have a $8.00 target price on the technology company’s stock, down from their prior target price of $14.00. Other analysts also recently issued reports about […]